PLoS One:C反应蛋白可用于严重卒中患者早期诊断肺炎

2016-03-14 phylis 译 MedSci原创

背景:由于体格检查困难,免疫状态的改变,影像学表现的延迟,使得卒中后合并肺炎的准确诊断收到挑战。本研究旨在描述卒中后肺炎早期的临床表现并检测C反应蛋白是否是卒中后肺炎的诊断标志物。方法:研究包括进行鼻饲的患者及卒中7天内无肺炎证据的患者,随访21天,每天进行临床检查。根据英国胸部协会改良标准诊断肺炎的发生。结果:招募60名患者(平均年龄77岁,平均NIHSS分数为19.47)。44例患者诊断为肺炎

背景:由于体格检查困难,免疫状态改变,影像学表现延迟,使得卒中后合并肺炎的准确诊断受到挑战。本研究旨在描述卒中后肺炎早期的临床表现,并且检测C反应蛋白是否是卒中后肺炎的诊断标志物。

方法:研究包括进行鼻饲的患者及卒中7天内无肺炎证据的患者,随访21天,每天进行临床检查。根据英国胸部协会改良标准诊断肺炎的发生。

结果:招募60名患者(平均年龄77岁,平均NIHSS分数为19.47)。44例患者诊断为肺炎。肺炎诊断当天的常见表现为为新出现的裂纹(43 / 44,98%)、呼吸急促>25次/分(42/44、95%),血氧饱和度<90%(41 / 44,93%)。27例(61%)患者发生咳嗽,25(57%)患者咳脓痰,15(34%)发热>38°C。38例(86%)患者白细胞(白细胞>11000个/毫升)升高,和43(97%)肺炎患者CRP增高(>10 mg/L)。CRP的ROC曲线下面积为0.827(95%可信区间0.720,0.933)。可接受诊断敏感性(> 0.8)CRP的界值点为25.60 mg/L(Youden指数(J)0.515;灵敏度0.848;特异性0.667)。界值为64.65毫克/升时,诊断准确率最高(J 0.562,敏感性0.636,特异性0.926)。

结论:重症脑卒中患者发生肺部感染,在疾病早期不常表现咳嗽、咳脓痰,这些诊断肺炎的关键症状。本研究最常见的症状是新出现的裂纹,呼吸急促,缺氧。研究结果表明,CRP>25 mg/L时应及时观察肺炎的发生,而当CRP值>65 mg/L,则肺炎诊断的准确性已经较高。

原文出处:

Warusevitane A, Karunatilake D, et al. Early Diagnosis of Pneumonia in Severe Stroke: Clinical Features and the Diagnostic Role of C-Reactive Protein. PLoS One. 2016 Mar 3.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1720100, encodeId=4b101e20100a6, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Nov 07 10:03:00 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789785, encodeId=af831e8978512, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Feb 01 05:03:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297809, encodeId=ef6a129e80933, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Wed Mar 16 08:03:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382636, encodeId=7bbc13826369b, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Mar 16 08:03:00 CST 2016, time=2016-03-16, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1720100, encodeId=4b101e20100a6, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Nov 07 10:03:00 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789785, encodeId=af831e8978512, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Feb 01 05:03:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297809, encodeId=ef6a129e80933, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Wed Mar 16 08:03:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382636, encodeId=7bbc13826369b, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Mar 16 08:03:00 CST 2016, time=2016-03-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1720100, encodeId=4b101e20100a6, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Nov 07 10:03:00 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789785, encodeId=af831e8978512, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Feb 01 05:03:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297809, encodeId=ef6a129e80933, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Wed Mar 16 08:03:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382636, encodeId=7bbc13826369b, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Mar 16 08:03:00 CST 2016, time=2016-03-16, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1720100, encodeId=4b101e20100a6, content=<a href='/topic/show?id=915c3604e6b' target=_blank style='color:#2F92EE;'>#卒中患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36047, encryptionId=915c3604e6b, topicName=卒中患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=940232842333, createdName=wangyang7969, createdTime=Mon Nov 07 10:03:00 CST 2016, time=2016-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1789785, encodeId=af831e8978512, content=<a href='/topic/show?id=6e4814388e2' target=_blank style='color:#2F92EE;'>#Plos one#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14388, encryptionId=6e4814388e2, topicName=Plos one)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fda6311, createdName=119337457, createdTime=Wed Feb 01 05:03:00 CST 2017, time=2017-02-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1297809, encodeId=ef6a129e80933, content=<a href='/topic/show?id=4eca5598c7' target=_blank style='color:#2F92EE;'>#C反应蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5598, encryptionId=4eca5598c7, topicName=C反应蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=20b5274, createdName=JR19860219, createdTime=Wed Mar 16 08:03:00 CST 2016, time=2016-03-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382636, encodeId=7bbc13826369b, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Wed Mar 16 08:03:00 CST 2016, time=2016-03-16, status=1, ipAttribution=)]

相关资讯

7种方法降C反应蛋白 让心梗远离你

多年来医生都专注于用基本措施来评估患者的健康状况,如血压、体重、胆固醇水平等。但近年来更多的研究发现针对心脏健康出现了一种新的最有价值预测方法:C反应蛋白(CRP)。据menshealth.com网站报道,尽管早在1930年医生们就发现了这种由肝脏生成的血浆蛋白,但只是在前几年医学界才发现它很重要。现在医生已了解到体内的CRP水平能帮助评估慢性炎症及

Clin Chim Acta:基线C反应蛋白较高与缺血性卒中风险增加相关

背景:有关超敏C-反应蛋白(hs-CRP)和卒中的风险之间的研究结果是相互矛盾的。目标:为确定基线hs-CRP升高的是否是不同类型的卒中的独立危险因素。方法:系统搜索PubMed、EMBASE、Cochrane图书馆、中国知网和万方数据库中2015年1月前发表的前瞻性观察性研究。研究报告超敏c反应蛋白水平和hs-CRP和不同卒中亚型的水平和校正风险评估值。总结果用校正风险比(RR)来表示,及相应的

Am Heart J: IL-6和CRP是房颤患者死亡和心血管事件发生的危险因素(RE-LY研究)

背景:炎症与心血管疾病和房颤(AF)相关。这项研究中,研究者评估房颤患者炎症标志物和未来心血管事件的发生的相关性。方法:随机化分析IL-6,CRP(n= 6187)和纤维蛋白原(n = 4893)。应用Cox模型和C-statistics评估预后。结果:校正临床危险因子后,IL-6与卒中或全身性栓塞,严重出血,血管性死亡和复合血栓栓塞预后(缺血性卒中,全身性栓塞,心肌梗死,肺栓塞和血管性死亡)相关

Neurology:常规的血液测试或可预测卒中发作风险

一项关于缺血性卒中的新发现可能允许医生们利用常见的血液测试和病人的基因特征来预测他们第二次卒中发作风险。 研究人员已发现高水平的C反应蛋白(C-Reactive Protein, CRP)---血液中发现的一种酶---与复发的缺血性卒中风险增加存在关联。CRP是由于肝脏对炎症作出反应而产生的,而且人们已经通过检测它来测量病人患上冠状动脉疾病的风险。这项新的研究提示着对缺血性卒中病

PLoS One:卒中后血浆CRP与卒中后疲劳并无相关

背景:脑卒中后疲劳是一种常见的、令人痛苦的问题,但很少有关于它的生物学机制的研究较少。这项队列研究是探讨脑卒中后C-反应蛋白(C反应蛋白)与卒中后疲劳的关系。方法:评估患者卒中后1月,6个月及12个月后,疲劳评估量表,卒中后疲劳定义,医院焦虑和抑郁量表,每天步数。收集患者血样,通过标准的CRP免疫测定CRP的水平。由Pearson相关和独立样本t检验判定每一时间点,CRP和疲劳之间的相关性。将抑郁

Neurology:CRP和CRP基因单核苷酸多态性均与卒中发生和再发相关

目的:调查缺血性脑卒中患者脑血管病的遗传因素及生物标志物的变化。方法:维生素干预预防脑卒中试验(VISP)是一项补充B族维生素预防再发性卒中,心肌梗死或死亡的随机,对照,临床试验。VISP收集基线时C反应性蛋白(CRP)、纤维蛋白原、肌酐、凝血酶原片段F1 +2、凝血酶抗凝血酶复合物,及治疗前的血浆血栓调节蛋白。对这些特征进行基因组范围内的关联扫描,并进行后续的复制分析。结果:研究者在检测VISP